• Mubritinib–HSA Interactions: Implications for Drug Pharmacok

  2026-04-21

  This study provides a molecular-level understanding of how mubritinib, a mitochondrial complex I inhibitor, interacts with human serum albumin (HSA). By combining multispectroscopic and molecular docking approaches, the research elucidates the binding affinity, site specificity, and impact on HSA’s structure and function, offering critical insights for optimizing drug pharmacokinetics and efficacy in cancer research.

• Epigenetic Regulation of PDK1 Drives TKI Resistance in Cance

  2026-04-21

  This study uncovers how epigenetic modifications of KDM3A and METTL16 elevate PDK1 expression, mediating resistance to EGFR-TKIs and promoting cancer progression. These findings reveal a novel regulatory axis and suggest new biomarkers and therapeutic targets for overcoming acquired drug resistance.

• USP7 Regulates Macrophage Polarization via PKM2 in SAP

  2026-04-20

  This study uncovers how ubiquitin-specific protease 7 (USP7) drives macrophage polarization in severe acute pancreatitis (SAP) through PKM2-mediated metabolic reprogramming. By integrating knockout and pharmacological inhibition approaches, the research highlights a mechanistic link between immune cell metabolism and inflammatory disease, offering a foundation for novel metabolic interventions.

• 3-Methyladenine in Neuroinflammation: Autophagy, Pain, and B

  2026-04-20

  Explore how 3-Methyladenine (3-MA) enables advanced autophagy and neuroinflammation research, bridging pain biology and cell signaling. Gain unique insights into PI3K pathway modulation and practical protocol guidance.

• BML-277: Advancing Chk2 Inhibition for Genome Stability Rese

  2026-04-19

  This thought-leadership article explores the mechanistic and strategic frontiers in DNA damage response research, focusing on the role of potent Chk2 inhibition by BML-277. Highlighting new insights into the Chk2–cGAS–TRIM41 axis and its translational impact, the article delivers actionable guidance for researchers in radioprotection, genome integrity, and cancer investigation, with protocol parameters and workflow recommendations uniquely structured for experimental reproducibility.

• FGFR1’s Obligatory Role in Early Human Adipogenesis Unveiled

  2026-04-18

  This study identifies fibroblast growth factor receptor 1 (FGFR1) as an essential regulator of early adipogenic events in human preadipocytes. By dissecting the interplay between growth factors and FGFR signaling, the paper advances understanding of adipocyte number regulation—highlighting potential targets for obesity intervention.

• APOL1 Evolution, APOL3 Interactions, and Isoforms in Renal I

  2026-04-17

  This article examines the multifaceted molecular mechanisms by which APOL1 variants, their evolutionary context, alternative splicing, and protein–protein interactions—particularly with APOL3—contribute to renal cell injury. The reference study integrates population genetics, isoform-specific functional analyses, and novel interaction mapping to advance mechanistic understanding of APOL1-driven kidney disease.

• Caspase-8 Fluorometric Assay Kit: Precision in Apoptosis Ass

  2026-04-16

  The Caspase-8 Fluorometric Assay Kit from APExBIO streamlines IETD-dependent caspase activity measurement, delivering sensitive, quantitative data for apoptosis and disease modeling. Leveraging recent cancer research advances, this guide details practical protocols, troubleshooting, and workflow optimization for robust programmed cell death research.

• TG003 Cdc2-like Kinase Inhibitor: Applied Workflows and Trou

  2026-04-15

  TG003, a potent Cdc2-like kinase inhibitor from APExBIO, is a benchmark tool for dissecting alternative splicing modulation and platinum resistance mechanisms. This guide delivers actionable protocols, troubleshooting strategies, and translational insights for researchers leveraging TG003 in exon-skipping therapy and cancer models.

• I-BET151 (GSK1210151A): Technical Guidance and Best Practice

  2026-04-14

  I-BET151 (GSK1210151A) provides researchers with a selective BET bromodomain inhibitor for dissecting transcriptional regulation in cancer biology, especially where BRD2, BRD3, or BRD4 are implicated. It is well-suited for apoptosis and cell cycle arrest assays in preclinical workflows, but should not be used for diagnostic or clinical applications.

• Honokiol: Advanced Strategies for Translational Oncology

  2026-04-13

  This thought-leadership article explores Honokiol—chemically 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol—as a next-generation tool for translational researchers seeking to interrogate cancer biology through precision modulation of NF-κB signaling, tumor angiogenesis, and immunometabolic pathways. Integrating mechanistic insights, experimental strategy, and competitive benchmarking, the article delivers actionable guidance while addressing stability and workflow considerations. We critically interpret in vitro response metrics from recent scholarship and escalate the discourse by proposing optimized experimental frameworks for Honokiol, with direct links to APExBIO’s research-grade product.

• L-NMMA Acetate for NOS Signaling: Protocols & Research Impac

  2026-04-12

  L-NMMA acetate empowers targeted modulation of the nitric oxide pathway, enabling high-fidelity dissection of inflammation and tissue regeneration models. Discover actionable workflows, troubleshooting strategies, and insights from the latest research to maximize experimental precision in NOS signaling studies.

• 5-Methyl-CTP: Elevating mRNA Vaccines Through Precision Engi

  2026-04-12

  Explore how 5-Methyl-CTP, a 5-methyl modified cytidine triphosphate, critically enhances mRNA vaccine stability and efficacy. This article uniquely bridges fundamental nucleotide chemistry with breakthrough evidence from large-animal mRNA immunization studies.

• Levofloxacin: Synthetic Fluoroquinolone for Advanced Assays

  2026-04-11

  Levofloxacin, a synthetic fluoroquinolone antibiotic, empowers researchers with precise inhibition of bacterial DNA replication and targeted modulation of osteoblast and chondrocyte activity. This guide translates high-impact resistance findings and practical assay enhancements into actionable protocols and troubleshooting strategies for both antibacterial and bone metabolism workflows.

• Lypressin Acetate: Protocol Enhancements for Vasopressor and

  2026-04-11

  Lypressin acetate offers precision and versatility for researchers probing GPCR signaling, vasopressor activity, and emerging antiviral mechanisms. This guide details optimized workflows, troubleshooting strategies, and actionable insights grounded in quantitative data and peer-reviewed evidence.

453 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page